| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Achlorhydria | D000126 | 1 associated lipids |
| Actinomycetales Infections | D000193 | 4 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Angina Pectoris | D000787 | 27 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Monno R et al. | Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. | 2001 | AIDS Patient Care STDS | pmid:11788074 |
| Yangco BG et al. | Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? | 2014 | AIDS Patient Care STDS | pmid:24833016 |
| Aboulafia DM | Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. | 2003 | AIDS Read | pmid:14524324 |
| Kahlon SS et al. | Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. | 2008 | AIDS Read | pmid:18975441 |
| Chu J et al. | Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. | 2011 | AIDS Res Ther | pmid:21388558 |
| Smibert OC et al. | Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. | 2017 | AIDS Res. Hum. Retroviruses | pmid:28791872 |
| Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
| Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
| Nagahara A et al. | Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207518 |
| Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
| Calvet X et al. | One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12144575 |
| Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
| O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
| Goodgame RW et al. | Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736715 |
| De Francesco V et al. | Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113366 |
| Gisbert JP and Calvet X | Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. | 2011 | Aliment. Pharmacol. Ther. | pmid:22017749 |
| Pellegrini M et al. | Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. | 2005 | Aliment. Pharmacol. Ther. | pmid:16098001 |
| Huang J and Hunt RH | Clarithromycin-based triple therapies. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102978 |
| Osato MS et al. | Comparative efficacy of new investigational agents against Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284777 |
| Klok RM et al. | Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966514 |